Krishna Institu.
Krishna Institu. Q2 FY26 earnings call: Revenue & Margins
Q2 FY26 earnings call: what management guided on revenue, margins and order book.
The short version
Telangana cluster expected to grow at high single-digit rate; growth to improve after commissioning of Kondapur hospital and rehabilitation of Secunderabad beds. KIMS expects new hospitals to become EBITDA neutral within 12 months of commissioning, with one Bangalore facility potentially slipping beyond the first quarter.
From Krishna Institu.'s Q2 FY26 earnings-call transcript · updated 16 Oct 2026.
Revenue & Sales Performance
- Telangana cluster expected to grow at high single-digit rate; growth to improve after commissioning of Kondapur hospital and rehabilitation of Secunderabad beds.
- Andhra Pradesh cluster aims for mid-teens to high-teens revenue growth driven by capacity additions and specialty expansions.
- New hospitals (e.g., Bangalore, Thane) targeted to ramp up within 12 months, becoming EBITDA neutral; anticipate strong volume buildup with large-format hospitals.
- Kondapur hospital expansion to 770 beds aimed at capturing unmet demand, expecting revenue around INR1,000 crore in the future.
- Pricing strategy across new markets (Nashik, Thane, Bangalore, Kerala) focuses on affordability to drive volume; positioning similar to Telangana and Andhra Pradesh.
2 more points from Krishna Institu.'s call on revenue
Pro opens every point from 15K+ earnings calls
Profitability & Margins
See what Krishna Institu. said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Kondapur unit bed expansion: Incremental 550 beds expected to commission over the next 6 months, bringing total beds to around 770.
- Secunderabad unit bed rehabilitation and addition: Possible increase from 1,000 to 1,200 beds over the next 3.5 years.
- New large-format hospitals in new markets (Nashik, Thane, Bangalore, Kerala) being developed with a focus on affordability and volume.
- Investments in advanced technology and infrastructure: Acquisition of Gamma Knife, magnetic resonance focused ultrasound, TULSA-PRO, and 25 DaVinci robotic machines to enhance treatment offerings.
- Continued focus on ramping up newly added bed capacities incrementally as occupancy improves—capex mostly incurred upfront with operationalization dependent on demand.
2 more points from Krishna Institu.'s call on capex
Pro opens every point from 15K+ earnings calls
Fundraising & Capital Structure
See what Krishna Institu. said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
2 more points from Krishna Institu.'s call on order book
Pro opens every point from 15K+ earnings calls
Krishna Institu. — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest (Q4 FY26): revenue ₹1.1K Cr, net profit ₹33 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Krishna Institute of Medical Sciences Ltd's management said in earlier quarters
Others in Healthcare Services this season
- Maitreya Medica. (Q2 FY26)
23.92 crore (Page 26). Key investor presentation takeaways from Maitreya Medica.'s Q2 FY26 investor presentation — and how it ranks against sector peers.
- Metropolis Healt (Q2 FY26)
Organic growth remains strong at around 12%, with no immediate price hikes planned. Key concall takeaways from Metropolis Healt's Q2 FY26 earnings call — and…
- 3B Blackbio (Q2 FY26)
Q2 FY 2025-26 sales: ₹3042.83 Lakh (including COVID sales ₹10.23 Lakh), up from ₹2457.55 Lakh in Q2 FY 2024-25. Key concall takeaways from 3B Blackbio DX Ltd's…
- Unihealth Hosp (Q2 FY26)
Nashik financial closure achieved via equity and bank debt (INR 22 crores from Bank of India). Key concall takeaways from Unihealth Hospitals Ltd's Q2 FY26…
Arthneeti Pro · Annual
Krishna Institu. and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Krishna Institu. Q2 FY26 results?
Telangana cluster expected to grow at high single-digit rate; growth to improve after commissioning of Kondapur hospital and rehabilitation of Secunderabad beds. KIMS expects new hospitals to become EBITDA neutral within 12 months of commissioning, with one Bangalore facility potentially slipping beyond the first quarter.
What is Krishna Institu. share price analysis?
Krishna Institu. currently shows a neutral. The stock trades at a P/E of 138.1 with a market cap of ₹28,796 Cr. Investors should review the full earnings analysis for detailed insights.
Is Krishna Institu. planning capital expenditure?
Kondapur unit bed expansion: Incremental 550 beds expected to commission over the next 6 months, bringing total beds to around 770.
Keep Krishna Institu. on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.